Article

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents

2022-08-24

Abstract excerpt

Human monoclonal antibodies from convalescent individuals that target the SARS-CoV-2 spike protein have been deployed as therapeutics against SARS-CoV-2. However, nearly all of these antibodies have been rendered obsolete by SARS-CoV-2 variants that evolved to resist similar, naturally occurring antibodies. Here, we describe the development of human monoclonal antibodies that bind the ACE2 receptor rather than the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a258e4e7-fe4f-5a9a-909c-2fdf5d31cdc2
DOI: 10.1101/2022.08.24.505169

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsDOI 10.1101/2022.08.24.505169Read

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodiesSemantic proximity Read

ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus BlockerSemantic proximity Read

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blockerSemantic proximity Read

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsSemantic proximity Read

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and aviditySemantic proximity Read

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2Semantic proximity Read

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.Semantic proximity Read

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsSemantic proximity Read

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variantsSemantic proximity Read

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptidesSemantic proximity Read